['non small cell lung cancer']
['azd9291']

        Inclusion Criteria:

          -  Histologically confirmed metastatic or recurrent stage IV NSCLC with activating EGFR
             mutation other than deletion in exon 19, L858R, T790M and insertion in exon 20

          -  metastatic or recurrent NSCLC

          -  Be 19years of age on day of signing informed consent

          -  ECOG performance status of 0 to 2

          -  At least one measurable lesion by RECIST 1.1(The part of radiation treatment in the
             palliative setting is excluded.)

          -  Untreated asymptomatic brain metastasis or symptomatic brain metastasis treated with
             local treatment such as operation, whole brain radiotherapy, or gamma-knife surgery

          -  At least 2 weeks later after whole brain radiotherapy or at least 4 weeks later after
             palliative thoracic radiotherapy

          -  Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5
             x 109/L; Hb > 9.0g/dL; platelets > 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or
             ALT < 2.5 ULN if no demonstrable liver metastases or < 5 UNL in the presence of liver
             metastases, CCr ≥ 50mL/min

          -  Written informed consent form

        Exclusion Criteria:

          -  Prior treatment with EGFR TKI

          -  Major surgery undertaken less than 4 weeks before the study

          -  Localized palliative radiotherapy unless completed more than 2 weeks before the study

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or
             arrhythmia

          -  Pregnant or nursing women (Women of reproductive potential have to agree to use an
             adequate contraceptive method)

          -  Uncontrolled symptomatic brain metastasis

          -  Prior history of malignancy within 5 years from study entry except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer, or
             well-treated thyroid cancer

          -  Concomitant use of CYP3A4 inducers/inhibitors

          -  Prolonged QT interval in ECG (QTc >450 msec)

          -  Prior history of interstitial lung disease
      